X4 Pharmaceuticals (XFOR) - צמיחת רווחים בשנה הנוכחית

Risks for X4 Pharmaceuticals (XFOR) are linked to the limited market for orphan drugs and R&D expenditures. The 12-month relative EPS growth indicator in the daily price action on the GURU.Markets chart helps track these trends, where the value remains at 66.30. The business relies on outsourced manufacturing and clinics, generating revenue from the sale of a patented drug for the treatment of leukocyte deficiency.

This indicator measures the year-over-year growth rate of earnings per share, allowing for an assessment of the business's actual efficiency. Growth in this value confirms the ability of X4 Pharmaceuticals (XFOR) to generate additional free cash flow. The EPS dynamics compared to last year clearly reflect the monetization of exclusive rights to the drug for the treatment of WHIM syndrome. The high margins of this protected niche should translate into a positive trend for the metric, which minimizes the risk of overpaying for the asset.